Loading…
Develops base-editing gene therapies that precisely rewrite single DNA letters to treat genetic diseases.
Develops base-editing gene therapies that precisely rewrite single DNA letters to treat genetic diseases.
Has no approved product, so its income is collaboration payments and money raised from investors, not sales. Value rests on moving its first treatments, such as BEAM-101 for sickle cell disease, through clinical trials. It also has research partnerships with larger drugmakers that pay upfront and milestone fees.
Moat: narrow (IP / patents, process know-how). Proprietary base-editing technology, more precise than CRISPR cutting, with broad foundational patents.
Headquarters: Cambridge, Massachusetts, US · Founded: 2017 · Employees: 511
Size Beam Therapeutics (BEAM) is a United States Health Care company (Biotechnology) with a market value of $2.73B, the 1601st largest of 3,117 United States companies the cockpit tracks. Shares closed at $26.41 on 6 Nov 2026.
Performance Over six months the shares fell 18.3%, against +2.3% for the median peer and -1.1% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 163.3% over the last twelve months (peer median +0.3%); the operating margin is -267.7% (peer median -19.5%).
Valuation It trades at 13.2× enterprise value to sales against a peer median of 14.2× (9th cheapest of 18).
Short interest Short interest is 25.4% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $147M | $140M | $63.5M | $378M | $60.9M |
| Revenue growth | — | +120% | -83% | +520% | — |
| Gross profit | $125M | $117M | $41.6M | $358M | $38.3M |
| EBITDA | -$370M | -$361M | -$394M | -$156M | -$316M |
| Net income | -$107M | -$80.0M | -$377M | -$133M | -$289M |
| Free cash flow | -$398M | -$360M | -$356M | -$183M | -$26.4M |
| Capital expenditure | $9.59M | $14.9M | $8.95M | $33.7M | $49.0M |
| Total debt | $244M | $154M | $161M | $173M | $182M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Beam Therapeutics BEAM | $2.73B | -18% | +163% | -268% | 13.2× | n/a |
| Intellia Therapeutics NTLA | $1.59B | -19% | +13% | -712% | 20.6× | n/a |
| CRISPR Therapeutics CRSP | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a |
| Editas Medicine EDIT | $395M | -17% | +21% | -178% | 5.4× | n/a |
| Vertex Pharmaceuticals VRTX | $139B | +27% | +11% | 35% | 10.7× | 6.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BEAM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.4% | -4.6% | 7th highest of 21 |
| 6-month return | -18.3% | +2.3% | 6th lowest of 20 |
| Distance from 52-week high | -31.0% | -30.9% | 11th highest of 21 |
| Revenue growth (TTM) | +163.3% | +0.3% | highest of 17 |
| Operating margin | -267.7% | -19.5% | 5th lowest of 17 |
| EV / Sales | 13.2× | 14.2× | 9th cheapest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics BEAM | United States | $2.73B | -18% | +163% | -268% | 13.2× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.71B | -12% | -23% | 5% | 10.3× | 31.3% | -3.8% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.76B | -23% | +18% | 27% | 4.7× | 0.5% | +36.0% |
| Xeris Biopharma XERS | United States | $2.77B | +133% | +36% | 11% | 8.8× | 33.3% | +70.2% |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.68B | -52% | 0% | -25% | 21.9× | n/a | n/a |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | 22.6× | n/a | n/a |
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 5.7× | -0.8% | +64.6% |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | 6.1× | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | 17.1× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.58B | n/a | n/a | n/a | 67.9× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 14.2× | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | 5.5× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 2.8× | -2.0% | +27.4% |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | 6,237.3× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | 45.9× | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 3.7× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | 128.0× | n/a | n/a |